Heart failure & cardiomyopathiesSecondary analysis
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure
- Secondary analysis of the DAPA-HF randomised trial
Authors' conclusion
In DAPA-HF, elevated CA125 levels were an independent predictor of the risk of worsening HF or cardiovascular death. Dapagliflozin reduced the risk of worsening HF or cardiovascular death regardless of baseline CA125.
Study context
- Population
- Patients with HFrEF in the DAPA-HF trialof 4,774 with CA125 data
- Participants
- 3,123 patients
- Comparison
- Outcomes by baseline CA125; dapagliflozin vs placebo by CA125
- Primary endpoint
- First episode of worsening heart failure (HF) or CV death
Primary result
As reported in the abstract
Worsening HF or CV death by baseline CA125
Adjusted hazard ratio (95% CI)
CA125 >35 U/mL vs CA125 ≤35 U/mL
1.59(1.29–1.96)
Q2 (8.79-13.04 U/mL) vs Q1 (≤8.78 U/mL)
0.94(0.71–1.24)
Q3 (13.05-21.13 U/mL) vs Q1 (≤8.78 U/mL)
1.22(0.94–1.59)
Q4 (≥21.14 U/mL) vs Q1 (≤8.78 U/mL)
1.63(1.28–2.09)
Further findings
| Outcome | placebo-corrected relative change (95% CI) | P value | |
|---|---|---|---|
| Placebo-corrected relative change in CA125 · 12 months | −5.2% (−10.6% to 0.5%) | P = 0.07 | |
| −15−10−505Difference (linear scale) |
Baseline CA125 · median baseline
- Median baseline CA125 (IQR: 8.78-21.13 U/mL), 3,123 of 4,774 patients with available data
- 13.04 U/mL
Effect of dapagliflozin vs placebo on primary outcome, by baseline CA125
- Benefit of dapagliflozin vs placebo consistent across CA125 quartiles
- interaction P = 0.13
- Benefit of dapagliflozin vs placebo consistent with CA125 as continuous variable
- interaction P = 0.75
Original publication
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure. J Am Coll Cardiol. Published 11 July 2023. doi:10.1016/j.jacc.2023.05.011
Summarised from the published abstract; every number is checked against it